INMB INMUNE BIO INC revenue, earnings and financials

For the quarter ended June 30, 2026, INMUNE BIO INC reported revenue of n/a, net income of −$1.27M and diluted EPS of −$0.05; for the fiscal year ended December 2025 revenue was $50.0K, up 257.1% on the year before.

INMB annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $50.0K, gross profit n/a, operating income −$47.4M, net income −$46.0M (margin -92000.0%), EPS −$1.86
• Fiscal year ended Dec 2024: revenue $14.0K, gross profit n/a, operating income −$42.6M, net income −$42.0M (margin -300000.0%), EPS −$2.11
• Fiscal year ended Dec 2023: revenue $155K, gross profit n/a, operating income −$29.7M, net income −$30.0M (margin -19354.8%), EPS −$1.67
• Fiscal year ended Dec 2022: revenue $374K, gross profit n/a, operating income −$26.0M, net income −$27.3M (margin -7299.2%), EPS −$1.52
• Fiscal year ended Dec 2021: revenue $181K, gross profit n/a, operating income −$29.2M, net income −$30.3M (margin -16762.4%), EPS −$1.88

INMB quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$1.27M, EPS −$0.05
• Quarter ended Mar 31, 2026: revenue n/a, net income −$5.41M, EPS −$0.20
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.33M, EPS −$0.14
• Quarter ended Sep 30, 2025: revenue n/a, net income −$6.47M, EPS −$0.24
• Quarter ended Jun 30, 2025: revenue n/a, net income −$24.5M, EPS −$1.05
• Quarter ended Mar 31, 2025: revenue $50.0K (up 257.1% year over year), net income −$9.74M, EPS −$0.43
• Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$9.14M, EPS −$0.40
• Quarter ended Sep 30, 2024: revenue n/a, net income −$12.1M, EPS −$0.60
• Quarter ended Jun 30, 2024: revenue n/a, net income −$9.75M, EPS −$0.50
• Quarter ended Mar 31, 2024: revenue $14.0K (down 63.2% year over year), net income −$11.0M, EPS −$0.61
• Quarter ended Dec 31, 2023 (from the annual report): revenue $28.0K (down 71.1% year over year), net income −$8.40M, EPS −$0.47
• Quarter ended Sep 30, 2023: revenue $43.0K (down 56.1% year over year), net income −$8.56M, EPS −$0.48
• Quarter ended Jun 30, 2023: revenue $46.0K (up 187.5% year over year), net income −$6.50M, EPS −$0.36
• Quarter ended Mar 31, 2023: revenue $38.0K (down 76.7% year over year), net income −$6.54M, EPS −$0.36
• Quarter ended Dec 31, 2022 (from the annual report): revenue $97.0K, net income −$5.83M, EPS −$0.32
• Quarter ended Sep 30, 2022: revenue $98.0K (up 600.0% year over year), net income −$7.73M, EPS −$0.43
• Quarter ended Jun 30, 2022: revenue $16.0K, net income −$6.84M, EPS −$0.38
• Quarter ended Mar 31, 2022: revenue $163K (up 3975.0% year over year), net income −$6.90M, EPS −$0.39
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.67M, EPS −$0.57
• Quarter ended Sep 30, 2021: revenue $14.0K, net income −$9.46M, EPS −$0.55

INMB cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$22.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$33.4M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$12.0M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$22.7M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$28.5M, share buybacks n/a

INMB balance sheet

• Jun 30, 2026: cash n/a, total assets $26.8M, total liabilities $6.48M, shareholders' equity $20.4M
• Mar 31, 2026: cash n/a, total assets $25.8M, total liabilities $6.19M, shareholders' equity $19.6M
• Dec 31, 2025: cash $24.8M, total assets $32.4M, total liabilities $8.83M, shareholders' equity $23.5M
• Sep 30, 2025: cash $27.7M, total assets $33.4M, total liabilities $7.98M, shareholders' equity $25.4M
• Jun 30, 2025: cash $33.4M, total assets $37.7M, total liabilities $8.82M, shareholders' equity $28.9M
• Mar 31, 2025: cash $19.3M, total assets $37.8M, total liabilities $8.13M, shareholders' equity $29.7M
• Dec 31, 2024: cash $20.9M, total assets $39.6M, total liabilities $7.47M, shareholders' equity $32.1M
• Sep 30, 2024: cash $33.6M, total assets $52.8M, total liabilities $14.1M, shareholders' equity $38.7M

What is INMB's revenue?

INMUNE BIO INC reported $50.0K of revenue for the fiscal year ended December 2025.

Is INMB profitable?

No. INMUNE BIO INC lost $18.5M over the last four quarters.

What is INMB's EPS?

Diluted earnings per share over the last four quarters were −$0.63; −$0.05 in the latest quarter.

INMB ownership and insider trades · All stocks